Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CorCap gets another shot

This article was originally published in The Gray Sheet

Executive Summary

FDA will reconsider approval of Acorn Cardiovascular's CorCap mesh wrap treatment for heart failure following completion of a 50-patient confirmatory trial, the firm announces May 9. In December, FDA's Medical Device Dispute Resolution Panel supported the agency's decision not to approve the cardiac support device, based on the firm's 2004 submission of a 300-patient randomized trial (1"The Gray Sheet" Jan. 1, 2007, p. 14). Acorn says it plans to begin the new study, which will have six-month follow-up, this summer, potentially leading to CorCap approval in late 2008 or early 2009. Completion of the trial will require Acorn to "immediately" raise $15 million, the firm says...
Advertisement

Related Content

Acorn Asks For More Help From Investors After FDA Panel Denies CorCap PMA
Acorn Asks For More Help From Investors After FDA Panel Denies CorCap PMA
Advertisement
UsernamePublicRestriction

Register

MT024784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel